Fremanezumab for Episodic and Chronic Migraine: Efficacy, Safety, and Clinical Use Dr. Radion

This patient-oriented review explains the role of fremanezumab in the prevention of episodic and chronic migraine. The article discusses how CGRP-targeting monoclonal antibodies work, who may benefit most from treatment, expected effectiveness, safety considerations, common side effects, and practical aspects of long-term migraine prevention. Fremanezumab is one of the most advanced preventive therapies currently available for migraine. Clinical studies have demonstrated significant reductions in migraine frequency, with many patients achieving at least a 50% reduction in monthly migraine attacks. Unlike traditional preventive medications, fremanezumab is administered once monthly and is generally well tolerated. Prepared by Dr. Radion Ignatiev, physician and headache specialist, this educational resource is intended to help patients better understand modern evidence-based options for migraine prevention and support informed discussions with their healthcare providers.